THE MEPHENYTOIN OXIDATION POLYMORPHISM IS PARTIALLY RESPONSIBLE FOR THE N-DEMETHYLATION OF IMIPRAMINE

被引:148
作者
SKJELBO, E
BROSEN, K
HALLAS, J
GRAM, LF
机构
[1] Department of Clinical Pharmacology, Institute of Medical Biology, Odense University, Odense
[2] Department of Clinical Pharmacology, DK-5000, Odense C
关键词
D O I
10.1038/clpt.1991.4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The metabolism of imipramine in six poor metabolizers of mephenytoin was compared with the metabolism of 16 extensive metabolizers of mephenytoin from an earlier study. Each subject was given single doses of 100 mg imipramine hydrochloride and 100 mg desipramine hydrochloride on separate occasions. Imipramine demethylation clearance was 0.74 L . min-1 (mean; range, 0.31-1.24) in poor metabolizers of mephenytoin compared with 1.43 L . min-1 (mean; range, 0.61-3.81) in extensive metabolizers of mephenytoin (p = 0.01, Mann-Whitney U test). It has previously been shown that the imipramine clearance by way of other pathways and desipramine oral clearance, both largely representing 2-hydroxylation, are considerably lower in poor metabolizers of sparteine than in extensive metabolizers of sparteine. In contrast, five subjects who were poor metabolizers of mephenytoin and extensive metabolizers of sparteine and a control group of 11 subjects who were extensive metabolizers of mephenytoin and sparteine showed no statistically significant difference with regard to these parameters. One subject who was a poor metabolizer of mephenytoin and sparteine had the lowest imipramine oral clearance of all 22 subjects studied. In conclusion, this and an earlier study show that the oxidation of imipramine is mediated by means of two different polymorphic P450 isozymes, 2-hydroxylation by way of the sparteine oxygenase (P450IID6) and demethylation by way of the mephenytoin oxygenase (P450IIC8).
引用
收藏
页码:18 / 23
页数:6
相关论文
共 31 条
[1]   THE DEBRISOQUINE HYDROXYLATION TEST PREDICTS STEADY-STATE PLASMA-LEVELS OF DESIPRAMINE [J].
BERTILSSON, L ;
ABERGWISTEDT, A .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 15 (03) :388-390
[2]   IMPORTANCE OF GENETIC-FACTORS IN THE REGULATION OF DIAZEPAM METABOLISM - RELATIONSHIP TO S-MEPHENYTOIN, BUT NOT DEBRISOQUIN, HYDROXYLATION PHENOTYPE [J].
BERTILSSON, L ;
HENTHORN, TK ;
SANZ, E ;
TYBRING, G ;
SAWE, J ;
VILLEN, T .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (04) :348-355
[3]  
BROSEN K, 1985, ACTA PHARMACOL TOX, V57, P357
[4]   IMIPRAMINE DEMETHYLATION AND HYDROXYLATION - IMPACT OF THE SPARTEINE OXIDATION PHENOTYPE [J].
BROSEN, K ;
OTTON, SV ;
GRAM, LF .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 40 (05) :543-549
[5]   STEADY-STATE CONCENTRATIONS OF IMIPRAMINE AND ITS METABOLITES IN RELATION TO THE SPARTEINE DEBRISOQUINE POLYMORPHISM [J].
BROSEN, K ;
KLYSNER, R ;
GRAM, LF ;
OTTON, SV ;
BECH, P ;
BERTILSSON, L .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 30 (06) :679-684
[6]   STEADY-STATE LEVELS OF IMIPRAMINE AND ITS METABOLITES - SIGNIFICANCE OF DOSE-DEPENDENT KINETICS [J].
BROSEN, K ;
GRAM, LF ;
KLYSNER, R ;
BECH, P .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 30 (01) :43-49
[7]   CLINICAL-SIGNIFICANCE OF THE SPARTEINE-DEBRISOQUINE OXIDATION POLYMORPHISM [J].
BROSEN, K ;
GRAM, LF .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 36 (06) :537-547
[8]   QUINIDINE INHIBITS THE 2-HYDROXYLATION OF IMIPRAMINE AND DESIPRAMINE BUT NOT THE DEMETHYLATION OF IMIPRAMINE [J].
BROSEN, K ;
GRAM, LF .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 37 (02) :155-160
[9]   1ST-PASS METABOLISM OF IMIPRAMINE AND DESIPRAMINE - IMPACT OF THE SPARTEINE OXIDATION PHENOTYPE [J].
BROSEN, K ;
GRAM, LF .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (04) :400-406
[10]  
DENCKER H, 1976, CLIN PHARMACOL THER, V19, P584